Prognostic/diagnostic testing and a raft of new drug targets from genomics promise to transform cardiovascular medicine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. World Health Statistics Quarterly 46, (1993) & World Health Statistics Quarterly 48, (1995 ); Eur. Heart J. 17, 1318– 1328 (1996).
American Heart Association (http://www.americanheart.org ).
Rodgers, A, et al. J. Hypertens. Suppl. 18, S3–S6 (2000).
Fox, K.A. Cardiovasc. Drugs Ther. 13, 211–216 (1999).
Hwang D.M. et al. Circulation 96, 4146–4203 (1997).
Li A et al. Am. J. Med. Genet. 86, 57–61 (1999).
Plebani, M. & Zaninotto, M. Int. J. Clin. Lab. Res. 29, 56–63 (1999)
Trigatti, B. & Rigotti, A. Int. J. Tissue React. 22, 29–37 (2000).
Galiatsou, E. et al. J. Nephrol. 13, 185–192 (2000).
Woods, L.L. Curr. Opin. Nephrol. Hypertens. 9, 419– 425 (2000).
Rights and permissions
About this article
Cite this article
Cardiovascular disease. Nat Biotechnol 18 (Suppl 10), IT15–IT17 (2000). https://doi.org/10.1038/80048
Issue Date:
DOI: https://doi.org/10.1038/80048
